Pfizer, CDM clean up at Doctors' Choice Awards

Share this article:
Professional ads for Pfizer's Chantix and Organon's NuvaRing were the year's top-rated as judged by physicians in the Association of Medical Media's fifth annual Doctors' Choice Awards.
The two-page Chantix ad, executed by Euro RSCG Life LM&P, was the top-scoring ad in the general practice category, while the one-page NuvaRing ad, by CommonHealth's Adient, took top honors in the specialty category.
The survey, which drew responses from 6,040 physicians, included 332 professional ads in 11 therapeutic categories among the 200 most widely advertised products for 2006.
Pfizer was the year's big winner with a total of five awards – for top scoring one- and two-page ads as well as the highest-ranked ads within the cardiovascular and anti-infective categories. Genentech/OSI, Merck and Organon each took two awards. On the agency side, Cline Davis & Mann was tops with four awards – three for Pfizer and one for Novo Nordisk's Novolog Flexpen -- while AbelsonTaylor, Euro RSCG Life LM&P and CommonHealth's Adient each won two.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.